

BeiGene

BeiGene Pipeline

October 20, 2020

BeiGene's Internal Pipeline

Three late-stage, and eight early-stage clinical assets

Global
China

ASSETS	PROGRAMS	DOSE ESC.	DOSE EXPANSION		PIVOTAL		FILED	MARKET
		PH1a	PH1b	PH2*	PH2**	PH3		
zanubrutinib *(BTK)*	**monotherapy**	*R/R MCL (Accelerated approval in the U.S. 11.14.19)*						
		WM† (MAA accepted 06.18.20), R/R MCL (NDA in Israel accepted 05.21.20)						
		R/R MCL, R/R CLL/SLL (Approved by NMPA in China 06.03.20)						
		R/R WM						
		1L CLL/SLL, R/R CLL/SLL						
		R/R MZL						
		Previously treated CLL/SLL (ibrutinib intolerant)						
	combination	*+rituximab 1L MCL*						
		+obinutuzumab R/R FL						
tislelizumab *(PD-1)*	**monotherapy**	*R/R cHL (approved 12.26.19), 2L+ UC (approved 04.10.20)*						
		2L/3L HCC						
		2L NSCLC, 1L HCC, 2L ESCC						
		R/R NK/T-cell lymphoma						
	+ chemo	*1L Non-Sq. NSCLC (sNDA accepted 06.19.20), 1L Sq. NSCLC (sNDA accepted 04.04.20)*						
		1L NPC, 1L SCLC, Stage II/IIIA NSCLC, Localized ESCC						
		1L GC, 1L ESCC						
	+ pamiparib *(PARP)* **+ zanubrutinib** *(BTK)*	*Solid tumors*						
		B-cell malignancies						
pamiparib *(PARP)*	**Monotherapy**	*1L platinum-sensitive GC maintenance*						
		2L platinum-sensitive OC maintenance						
		3L gBRCA+ OC						
		HER2- BRCA mutated breast cancer						
		Solid tumors						
	+ TMZ *(chemo)*	*Solid tumors*						
	+ RT/TMZ *(RT/chemo)*	*Glioblastoma*						
lifirafenib *(RAF Dimer)*	**Monotherapy**	*B-Raf- or K-RAS/N-RAS-mutated solid tumors*						
		B-Raf- or K-RAS/N-RAS-mutated solid tumors						
BGB-A333 *(PD-L1)*	**monotherapy & + tislelizumab**	*Solid tumors*						
BGB-A425 *(TIM-3)*	**monotherapy & + tislelizumab**	*Solid tumors*						
BGB-A1217 *(TIGIT)*	**+ tislelizumab**	*Solid tumors*						
BGB-A445 *(OX40)*	**+ tislelizumab**	*Solid tumors*						
BGB-11417 *(Bcl-2)*	**monotherapy & + zanubrutinib**	*B-cell malignancies*						
BGB-10188 *(PI3-Kδ)*	**mono; + tislelizumab; + zanubrutinib**	*B-cell malignancies; Solid tumors*						
BGB-15025 *(HPK1)*	**monotherapy & + tislelizumab**	*IND enabling studies ongoing*						

*Some indications will not require a non-pivotal Ph2 clinical trial prior to beginning pivotal Ph2 or Ph3 clinical trials. **Confirmatory clinical trials post approval are required for accelerated approvals. † R/R or not suitable for chemo-immunotherapy 1. By MapKure, a JV with SpringWorks

BeiGene's Collaborative Pipeline

Over 20 compounds

Global
China

COMPOUND	(TARGET) / PROGRAM	DOSE ESC.	DOSE EXPANSION		PIVOTAL		COMMERCIAL RIGHTS	PARTNER
		PH1a	PH1b	PH2*	PH2**	PH3		
AMG 510	(KRAS G12C)	Solid Tumors, NSCLC, CRC					China	Amgen
AMG 701^^	(BCMA)	MM						
AMG 176	(Mcl-1, SM (i.v.))	Hematologic malignancies						
AMG 397	(Mcl-1, SM (oral))	Hematologic malignancies						
AMG 330^	(CD33)	Myeloid malignancies						
AMG 673^^	(CD33)	AML						
AMG 427^^	(FLT3)	AML						
AMG 562^^	(CD19)	NHL						
AMG 596^	(EGFRvIII)	Glioblastoma						
AMG 757^^	(DLL3)	SCLC						
AMG 160^^	(PSMA)	Prostate cancer						
AMG 506	(FAP x 4-1BB, DARPin®)	Solid Tumors						
AMG 199^^	(MUC17)	GC/GEJC						
Sitravatinib	(multi-kinase inhibitor) + tislelizumab Mono, + tislelizumab	NSCLC, RCC, OC, MEL HCC, GC/GEJC					Asia ex-Japan, AU, NZ	Mirati
Zanidatamab†	(HER2, bispecific antibody)	Breast cancer, GEA					Asia ex-Japan, AU, NZ	Zymeworks
ZW49	(HER2, bispecific ADC)	Planned (in Ph1 ex-China by Zymeworks)					Asia ex-Japan, AU, NZ	Zymeworks
BGB-3245	(B-RAF)	Solid tumors					Asia ex-Japan	SpringWorks[1]
BA3017	(CTLA4) Mono, + tislelizumab	Phase 1 study startup ongoing					Global	BioAtla
SEA-CD70	(anti-CD70)	Planned (starting Ph.1 ex-Asia by Seattle Genetics)					Asia ex-Japan, AU, NZ	Seattle Genetics
DKN-01	(DKK1) + tislelizumab ± chemo	Trials in GC/GEJ planned					Asia ex-Japan, AU,NZ	Leap Therapeutics
ABI-H0731	(HBV core inhibitor)	Chronic Hepatitis B Virus					China	Assembly Bio
ABI-H2158	(HBV core inhibitor)	Chronic Hepatitis B Virus						
ABI-H3733	(HBV core inhibitor)	Chronic Hepatitis B Virus						

Addition compounds from Amgen collaboration not yet disclosed

* Some indications will not require a non-pivotal Ph2 clinical trial prior to beginning pivotal Ph2 or Ph3 clinical trials. **Confirmatory clinical trials post approval are required for accelerated approvals. ^ BiTE, ^^ HLE BiTE, † ZW25, AML: acute myeloid leukemia, HLE BiTE: Half-life extended Bi-specific T-cell engagers, GC/GEJ: gastric cancer/gastroesophageal junction, HCC: hepatocellular carcinoma, IND: Investigational New Drug, MEL: melanoma, MM: multiple myeloma, NHL: non-Hodgkin's lymphoma, N/SCLC: non-/small cell lung cancer, OC: ovarian cancer, RCC: renal cell carcinoma, SM: small molecule; 1. By MapKure, a JV with SpringWorks